What topics does this cannabis study cover?

This study covers research on: THC, CBD, Pain, Nausea, Sleep, Inflammation.

Where was this research published?

Published in Phytotherapy research : PTR on June 23, 2026.

Evidence shows cannabis helps some conditions, but quality research remains limited

Q: What did this Review find?

This comprehensive overview analyzed **102 systematic reviews** examining the safety and effectiveness of cannabis derivatives for treating various medical conditions. The research found that only **17.6% of reviews met high methodological standards**, with the majority (68.6%) having critical quali

Efficacy and Safety of Cannabis Derivates and Their Synthetic Analogs. Overview of Systematic Reviews.

Phytotherapy research : PTR • June 23, 2026 • Review • Moderately Relevant

🤖

AI Summary

This comprehensive overview analyzed 102 systematic reviews examining the safety and effectiveness of cannabis derivatives for treating various medical conditions. The research found that only 17.6% of reviews met high methodological standards, with the majority (68.6%) having critical quality limitations. This highlights a significant gap in the current evidence base and suggests that many cannabis research conclusions should be interpreted cautiously.

The review identified moderate evidence supporting cannabis use for five conditions: ulcerative colitis, chronic non-cancer pain, Crohn's disease, multiple sclerosis, and post-chemotherapy nausea and vomiting. However, the evidence showed no benefits for sleep disorders, chronic cancer pain refractory to opioids, pain from radiotherapy, and palliative care pain. For many other conditions, evidence was either very limited or not yet evaluated, pointing to substantial gaps in current cannabis research that need addressing through higher-quality clinical trials.

The overview emphasizes that while cannabis derivatives show promise for certain inflammatory and pain conditions, decision-makers and healthcare providers must carefully evaluate the quality of evidence when considering recommendations. The authors stress the critical importance of conducting more rigorous primary studies and comprehensive safety assessments before making formal clinical guidelines, as the field currently suffers from too many low-quality reviews making conclusions difficult to trust.

📄 Original Abstract

The use of medicinal products derived from cannabis and its synthetic analogues has grown in recent years for various health conditions, which led to an increase in systematic reviews (SR) on the topic. The objective of this overview was to identify, synthesize, and critically appraise the evidence from SR on the benefits and harms of cannabis derivatives when used for therapeutic purposes in different health conditions. A comprehensive search was conducted to identify all relevant SR in Embase, Epistemonikos, MEDLINE, and Cochrane Database of Systematic Reviews. The inclusion criteria was SR assessing the effects of cannabis and its derivatives for any clinical condition that included only randomized controlled trials. A structured selection and extraction process was performed by two independent researchers. The methodological quality of the included SR was assessed using AMSTAR-2. This overview included 102 SR, 68.6% of which were of critically low quality and 17.6% were of high quality. There is low to moderate certainty of evidence of benefits from these interventions for ulcerative colitis, chronic non-cancer pain, Crohn's disease, multiple sclerosis, and post-chemotherapy nausea and vomiting. The results point to a lack of benefits for sleep disorders, chronic cancer pain refractory to opioids, pain related to radiotherapy, and pain in people receiving palliative care. For other conditions, the certainty of the evidence was very low or not assessed. This overview opens a broad and complex field for the development of primary studies to evaluate the effects of cannabinoids as primary or adjunctive therapy for different health conditions and reinforces the importance of safety assessment. Decision-makers and guideline developers can be guided by the results summarized in this overview. However, when making formal recommendations, it is essential to consider the quality of the SR and the certainty of the evidence identified for each outcome.

Paper Type

📚 Review

Publication

Journal: Phytotherapy research : PTR
Published: June 23, 2026
PMID: 42334060
DOI: 10.1002/ptr.70403

Authors (6)

Rafael Leite Pacheco Centro Universitário São Camilo, Medicine, São Paulo, Brazil.
Daniela Fortunato Rêgo Ministério dos Direitos Humanos e da Cidadania, Brasília, Distrito Federal, Brazil.
Carolina de Oliveira Cruz Latorraca Centro Universitário São Camilo, Medicine, São Paulo, Brazil.
Marco Aurelio de Carvalho Nascimento Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
André Bastos Daher Plataforma de Pesquisa Clínica da Fiocruz, Vice Presidency of Research and Biological Collections (VPPCB), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
+1 more authors